Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

SRC kinase regulation in progressively invasive cancer.

Xu W, Allbritton N, Lawrence DS.

PLoS One. 2012;7(11):e48867. doi: 10.1371/journal.pone.0048867. Epub 2012 Nov 7.

2.

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE.

Oncogene. 2010 Jun 3;29(22):3208-16. doi: 10.1038/onc.2010.103. Epub 2010 Apr 12.

3.

[FAK/c-Src signaling pathway mediates the expression of cell surface HSP90 in cultured human prostate cancer cells and its association with their invasive capability].

Liu XG, Guo Y, Yan ZQ, Guo MY, Zhang ZG, Guo CA.

Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):340-4. Chinese.

PMID:
21875461
4.

Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.

Wu W, Yang Q, Fung KM, Humphreys MR, Brame LS, Cao A, Fang YT, Shih PT, Kropp BP, Lin HK.

Mol Cell Endocrinol. 2014 Mar 5;383(1-2):69-79. doi: 10.1016/j.mce.2013.11.017. Epub 2013 Dec 1.

PMID:
24296312
5.

Src-dependent Tks5 phosphorylation regulates invadopodia-associated invasion in prostate cancer cells.

Burger KL, Learman BS, Boucherle AK, Sirintrapun SJ, Isom S, Díaz B, Courtneidge SA, Seals DF.

Prostate. 2014 Feb;74(2):134-48. doi: 10.1002/pros.22735. Epub 2013 Oct 30.

6.

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ.

Oncogene. 2004 Mar 18;23(12):2197-205.

PMID:
14767470
7.

The role of Src in prostate cancer.

Fizazi K.

Ann Oncol. 2007 Nov;18(11):1765-73. Epub 2007 Apr 10. Review.

PMID:
17426060
8.

Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells.

Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT.

Oncogene. 2001 Mar 8;20(10):1152-63.

9.

Global tyrosine kinome profiling of human thyroid tumors identifies Src as a promising target for invasive cancers.

Cho NL, Lin CI, Du J, Whang EE, Ito H, Moore FD Jr, Ruan DT.

Biochem Biophys Res Commun. 2012 May 11;421(3):508-13. doi: 10.1016/j.bbrc.2012.04.034. Epub 2012 Apr 10.

PMID:
22521882
10.

Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP.

Oncogene. 2008 Oct 23;27(49):6365-75. doi: 10.1038/onc.2008.250. Epub 2008 Aug 4.

11.

Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.

Rice L, Lepler S, Pampo C, Siemann DW.

Clin Exp Metastasis. 2012 Feb;29(2):133-42. doi: 10.1007/s10585-011-9436-2. Epub 2011 Dec 1.

PMID:
22130962
12.

Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasion.

Fiordalisi JJ, Dewar BJ, Graves LM, Madigan JP, Cox AD.

PLoS One. 2013 May 17;8(5):e64309. doi: 10.1371/journal.pone.0064309. Print 2013.

13.

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.

14.
15.

Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells.

Leroy C, Fialin C, Sirvent A, Simon V, Urbach S, Poncet J, Robert B, Jouin P, Roche S.

Cancer Res. 2009 Mar 15;69(6):2279-86. doi: 10.1158/0008-5472.CAN-08-2354. Epub 2009 Mar 10.

16.

Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer.

Paronetto MP, Farini D, Sammarco I, Maturo G, Vespasiani G, Geremia R, Rossi P, Sette C.

Am J Pathol. 2004 Apr;164(4):1243-51.

17.

Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529.

Kang S, Dong S, Guo A, Ruan H, Lonial S, Khoury HJ, Gu TL, Chen J.

J Biol Chem. 2008 Feb 22;283(8):4652-7. Epub 2007 Dec 21.

18.

Ligand-independent activation of MET through IGF-1/IGF-1R signaling.

Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE.

Int J Cancer. 2013 Oct 1;133(7):1536-46. doi: 10.1002/ijc.28169. Epub 2013 Apr 17.

19.

CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.

Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Andò S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG.

Cancer Res. 2014 Dec 1;74(23):7103-14. doi: 10.1158/0008-5472.CAN-14-0612.

20.

Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.

Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A, Bilancio A, Varricchio L, Ciociola A, Auricchio F.

Cancer Res. 2005 Nov 15;65(22):10585-93.

Supplemental Content

Support Center